David S Goldstein, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
6
6
2
N/A
0
11
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Robert B Innis, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
Mark Hallett, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Shared therapeutic areas:
Worked with same sponsors:
Eric M Wassermann, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Shared therapeutic areas:
Worked with same sponsors:
Carlos A Zarate, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Paolo Bonato, PhD
Spaulding Rehabilitation Hospital
Shared therapeutic areas:
Herbert B Slade, MD
Healthpoint
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Suman Sheraz, PhD*
Riphah International University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?
Clinical Autonomic Disorders: A Training Protocol
Biomarkers of Risk of Parkinson Disease
Reference Values for Plasma Catechols
Evaluation of Primary Chronic Autonomic Failure
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
All 6 trials loaded